3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
214
Lung Neoplasms
74
Neoplasms
24
Adenocarcinoma of Lung
16
Neoplasm Metastasis
15
Mesothelioma, Malignant
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Mesothelioma
12
Carcinoma
11
Head and Neck Neoplasms
10
Breast Neoplasms
8
Adenocarcinoma, Bronchiolo-Alveolar
7
Small Cell Lung Carcinoma
6
Ovarian Neoplasms
6
Recurrence
5
Pancreatic Neoplasms
4
Colorectal Neoplasms
4
Adenocarcinoma
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Lung Diseases
3
Laryngeal Diseases
3
Carcinoma, Small Cell
3
Brain Neoplasms
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Thoracic Neoplasms
2
Solitary Fibrous Tumor, Pleural
2
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Non Small Cell Lung Cancer NSCLC
×
Pemetrexed
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA